Cortex Neurology

06/12/2024

06/09/2023

🏥🫶🩺| En el Día de la Excelencia del Servicio al Prójimo reiteramos nuestro compromiso de ofrecer un servicio de calidad a nuestros pacientes con respeto, empatía y dedicación. Nos sentimos orgullosos por el privilegio y la oportunidad de servir al prójimo desde el corazón, y de darle continuidad al legado de servicio del Dr. Federico Trilla. Somos Compromiso. Somos Servicio. Somos Excelencia. ¡Feliz Día del Servicio al Prójimo!

03/08/2023

https://n.neurology.org/content/early/2023/07/21/WNL.0000000000207505

Lecanemab, a novel amyloid-sequestering agent, recently received accelerated FDA approval for the treatment of mild Dementia due to Alzheimer Disease (AD) and Mild Cognitive Impairment (MCI). Approval was based on a large Phase 3 trial, Clarity, which demonstrated reductions in amyloid plaque burden...

02/08/2023

https://n.neurology.org/content/early/2023/07/26/WNL.0000000000207757

With recent data demonstrating that lecanemab treatment can slow cognitive and functional decline in early symptomatic Alzheimer disease (AD), it is widely anticipated that this drug and potentially other monoclonal antibody infusions targeting amyloid-β protein will imminently be realistic options...

01/08/2023

https://www.alz.org/alzheimers-dementia/treatments/lecanemab-leqembi

Lecanemab (Leqembi™) has received accelerated approval as a treatment for early Alzheimer’s from the U.S. Food and Drug Administration.

31/07/2023

The U.S. Food and Drug Administration on Thursday granted standard approval to Eisai and Biogen's Leqembi for patients with Alzheimer's disease.

31/07/2023

https://www.statnews.com/2023/06/16/the-fda-needs-a-risk-evaluation-and-mitigation-strategy-for-alzheimers-drug-lecanemab/

The problem with the new Alzheimer’s drugs isn’t the drugs.